Sarcoma immunotherapy

Launce G. Gouw, Kevin B. Jones, Sunil Sharma, R Randall

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Much of our knowledge regarding cancer immunotherapy has been derived from sarcoma models. However, translation of preclinical findings to bedside success has been limited in this disease, though several intriguing clinical studies hint at the potential efficacy of this treatment modality. The rarity and heterogeneity of tumors of mesenchymal origin continues to be a challenge from a therapeutic standpoint. Nonetheless, sarcomas remain attractive targets for immunotherapy, as they can be characterized by specific epitopes, either from their mesenchymal origins or specific alterations in gene products. To date, standard vaccine trials have proven disappointing, likely due to mechanisms by which tumors equilibrate with and ultimately escape immune surveillance. More sophisticated approaches will likely require multimodal techniques, both by enhancing immunity, but also geared towards overcoming innate mechanisms of immunosuppression that favor tumorigenesis.

Original languageEnglish (US)
Pages (from-to)4139-4150
Number of pages12
JournalCancers
Volume3
Issue number4
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Sarcoma
Immunotherapy
Neoplasms
Immunosuppression
Epitopes
Immunity
Carcinogenesis
Vaccines
Genes
Therapeutics
Clinical Studies

Keywords

  • Immunosurveillance
  • Immunotherapy
  • Sarcoma
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gouw, L. G., Jones, K. B., Sharma, S., & Randall, R. (2011). Sarcoma immunotherapy. Cancers, 3(4), 4139-4150. https://doi.org/10.3390/cancers3044139

Sarcoma immunotherapy. / Gouw, Launce G.; Jones, Kevin B.; Sharma, Sunil; Randall, R.

In: Cancers, Vol. 3, No. 4, 01.12.2011, p. 4139-4150.

Research output: Contribution to journalReview article

Gouw, LG, Jones, KB, Sharma, S & Randall, R 2011, 'Sarcoma immunotherapy', Cancers, vol. 3, no. 4, pp. 4139-4150. https://doi.org/10.3390/cancers3044139
Gouw LG, Jones KB, Sharma S, Randall R. Sarcoma immunotherapy. Cancers. 2011 Dec 1;3(4):4139-4150. https://doi.org/10.3390/cancers3044139
Gouw, Launce G. ; Jones, Kevin B. ; Sharma, Sunil ; Randall, R. / Sarcoma immunotherapy. In: Cancers. 2011 ; Vol. 3, No. 4. pp. 4139-4150.
@article{61b4f689dcfd4031b5bd2cb8d3136ba7,
title = "Sarcoma immunotherapy",
abstract = "Much of our knowledge regarding cancer immunotherapy has been derived from sarcoma models. However, translation of preclinical findings to bedside success has been limited in this disease, though several intriguing clinical studies hint at the potential efficacy of this treatment modality. The rarity and heterogeneity of tumors of mesenchymal origin continues to be a challenge from a therapeutic standpoint. Nonetheless, sarcomas remain attractive targets for immunotherapy, as they can be characterized by specific epitopes, either from their mesenchymal origins or specific alterations in gene products. To date, standard vaccine trials have proven disappointing, likely due to mechanisms by which tumors equilibrate with and ultimately escape immune surveillance. More sophisticated approaches will likely require multimodal techniques, both by enhancing immunity, but also geared towards overcoming innate mechanisms of immunosuppression that favor tumorigenesis.",
keywords = "Immunosurveillance, Immunotherapy, Sarcoma, Vaccine",
author = "Gouw, {Launce G.} and Jones, {Kevin B.} and Sunil Sharma and R Randall",
year = "2011",
month = "12",
day = "1",
doi = "10.3390/cancers3044139",
language = "English (US)",
volume = "3",
pages = "4139--4150",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - Sarcoma immunotherapy

AU - Gouw, Launce G.

AU - Jones, Kevin B.

AU - Sharma, Sunil

AU - Randall, R

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Much of our knowledge regarding cancer immunotherapy has been derived from sarcoma models. However, translation of preclinical findings to bedside success has been limited in this disease, though several intriguing clinical studies hint at the potential efficacy of this treatment modality. The rarity and heterogeneity of tumors of mesenchymal origin continues to be a challenge from a therapeutic standpoint. Nonetheless, sarcomas remain attractive targets for immunotherapy, as they can be characterized by specific epitopes, either from their mesenchymal origins or specific alterations in gene products. To date, standard vaccine trials have proven disappointing, likely due to mechanisms by which tumors equilibrate with and ultimately escape immune surveillance. More sophisticated approaches will likely require multimodal techniques, both by enhancing immunity, but also geared towards overcoming innate mechanisms of immunosuppression that favor tumorigenesis.

AB - Much of our knowledge regarding cancer immunotherapy has been derived from sarcoma models. However, translation of preclinical findings to bedside success has been limited in this disease, though several intriguing clinical studies hint at the potential efficacy of this treatment modality. The rarity and heterogeneity of tumors of mesenchymal origin continues to be a challenge from a therapeutic standpoint. Nonetheless, sarcomas remain attractive targets for immunotherapy, as they can be characterized by specific epitopes, either from their mesenchymal origins or specific alterations in gene products. To date, standard vaccine trials have proven disappointing, likely due to mechanisms by which tumors equilibrate with and ultimately escape immune surveillance. More sophisticated approaches will likely require multimodal techniques, both by enhancing immunity, but also geared towards overcoming innate mechanisms of immunosuppression that favor tumorigenesis.

KW - Immunosurveillance

KW - Immunotherapy

KW - Sarcoma

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84055184517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055184517&partnerID=8YFLogxK

U2 - 10.3390/cancers3044139

DO - 10.3390/cancers3044139

M3 - Review article

VL - 3

SP - 4139

EP - 4150

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 4

ER -